newsfilter
← Latest News
GlobeNewswire·

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase